Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.80 USD
Change Today -0.01 / -0.15%
Volume 27.1K
KIN On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

kindred biosciences inc (KIN) Snapshot

Open
$6.83
Previous Close
$6.81
Day High
$6.85
Day Low
$6.77
52 Week High
06/10/14 - $19.74
52 Week Low
12/4/14 - $5.98
Market Cap
134.2M
Average Volume 10 Days
70.1K
EPS TTM
$-1.41
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KINDRED BIOSCIENCES INC (KIN)

Related News

No related news articles were found.

kindred biosciences inc (KIN) Related Businessweek News

View More BusinessWeek News

kindred biosciences inc (KIN) Details

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-506 for the treatment of inflammatory and autoimmune diseases; KIND-507 for the treatment of immune-mediated diseases; KIND-504, a cancer vaccine; and KIND-501, an antiangiogenic biologic for cancer in dogs. The company was founded in 2012 and is headquartered in Burlingame, California.

43 Employees
Last Reported Date: 03/13/15
Founded in 2012

kindred biosciences inc (KIN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $495.5K
Co-Founder, Chief Operating Officer and Secre...
Total Annual Compensation: $386.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.

kindred biosciences inc (KIN) Key Developments

Kindred Biosciences, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Kindred Biosciences, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company loss from operations of $6,762,000 against $6,177,000 a year ago. Net loss was $6,732,000 against $6,168,000 a year ago. Basic and diluted net loss per share was $0.34 against $0.38 a year ago.

Kindred Biosciences, Inc. Presents at Jefferies 2015 Animal Health Summit, Mar-26-2015 01:30 PM

Kindred Biosciences, Inc. Presents at Jefferies 2015 Animal Health Summit, Mar-26-2015 01:30 PM. Venue: New York, New York, United States. Speakers: Denise M. Bevers, Co-Founder, Chief Operating Officer and Secretary.

Kindred Biosciences Announces Positive Results of Pilot Field Study of KIND-012 for the Control of Fever in Horses

Kindred Biosciences, Inc. announced positive results from its pilot field study of KIND-012 for the control of pyrexia (fever) in horses. This study, which is the equivalent of a Phase 2 study, was a randomized, blinded, placebo-controlled, crossover study that enrolled 31 adult horses. The primary endpoint was improvement or resolution of fever. In the first treatment period, the response rate was 66.7% in the KIND-012 group vs. 12.5% in the placebo group (p=0.0032). In the second treatment period, the response rate was 57.1% in the KIND-012 group versus 0% in the placebo group (p=0.0019). KindredBio is planning to start a pivotal field study required for FDA approval of KIND-012 for the control of fever in horses.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KIN:US $6.80 USD -0.01

KIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aratana Therapeutics Inc $13.41 USD -0.10
View Industry Companies
 

Industry Analysis

KIN

Industry Average

Valuation KIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KINDRED BIOSCIENCES INC, please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.